secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001213900-23-085558
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics reports Q3 net loss $2.3M; INT230-6 shows 93% disease control in sarcoma
--------------------------------------------------------------------------------

- Phase 1/2 INT230-6 data in refractory soft tissue sarcoma: 93% disease control rate, survival extension ~15 months vs synthetic control.
- Received Orphan Drug Designation for all three components of INT230-6 for soft tissue sarcoma.
- Completed upsized IPO with full over-allotment, net proceeds $20.2M; cash $15.6M as of Sept 30, 2023.
- R&D expenses $1.4M, G&A $1.1M; net operating loss $2.3M for Q3 2023.
- On track to file IND for Phase 3 study in sarcoma and report Phase 2 breast cancer results by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023085558/0001213900-23-085558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023085558/ea188196-8k_intensity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-085558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer